Virtual Grand Rounds: Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk

This virtual grand rounds reviews recent evidence and guidance on combining an anticoagulant with antiplatelet therapy after stenting in CAD and PAD.

Live Broadcast
1.00 available credits
Information
October 20, 2020
12:00 PM - 01:00 PM EDT
Online
Virtual Grand Rounds: Redefining the Roles of Antithrombotic and Antiplatelet Therapies in Reducing CAD and PAD Residual Risk
Choose a format
Details
Presenters
Related
Comments
  • Overview

    Dr. Angiolillo (University of Florida College of Medicine – Jacksonville) provides an informative and succinct contemporary overview of antithrombotic use after an acute coronary syndrome (ACS) in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Using a lively, case-based format, Dr. Angiolillo discusses the challenges of antiplatelet use to prevent thrombosis post discharge after an ACS, the role of anticoagulation in ACS, and the role of triple antithrombotic therapy in ACS.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, the Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

    Faculty:
    Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
    Professor of Medicine
    Director, Cardiovascular Research
    Program Director, Interventional Cardiology Fellowship
    University of Florida College of Medicine -Jacksonville
    Jacksonville, FL 

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 

    Consulting Fees or Honoraria: Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company
    Payments for participation in review activities: CeloNova and St Jude Medical
    Institutional Research Grants: Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. 

    Reviewers/Content Planners/Authors:

    • The PIM planners and managers have nothing to disclose.
    • Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose. 
    • The Medtelligence planners and managers have nothing to disclose.
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Learning Objectives

    This case-based educational program is designed by distinguished experts in the field to provide the healthcare professional with information and guidance on the clinical issues and recent data regarding anticoagulation in patients with CAD and PAD. After participating in this educational activity, participants should be better able to:

    • Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
    • Relate the clinical implications of anticoagulation in patients with coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular diseases
    • Utilize non-VKA oral anticoagulants (NOACs) at the proper dose for patients with moderate or high risk of major polyvascular events, advising patients of the risks and benefits, and performing proper follow-up
    • Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, interventional cardiologists, internists, fellows, medical students, pharmacy professionals, and allied health professionals involved in the care of patients with CAD and PAD.

  • Accreditation and Credit Designation Statements

    Physician Continuing Education Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for
    Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and
    Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education
    for physicians.

    Credit Designation
    The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Evaluation by Course” and search by course ID 13277. Upon registering and successfully completing  the activity evaluation, your certificate will be made available immediately. 

  • Provider(s)/Educational Partner(s)

    Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in collaboration with Postgraduate Institute for Medicine (PIM).

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in conjunction with PIM. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Details
Presenters
Related
Comments
  • Overview

    Dr. Angiolillo (University of Florida College of Medicine – Jacksonville) provides an informative and succinct contemporary overview of antithrombotic use after an acute coronary syndrome (ACS) in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Using a lively, case-based format, Dr. Angiolillo discusses the challenges of antiplatelet use to prevent thrombosis post discharge after an ACS, the role of anticoagulation in ACS, and the role of triple antithrombotic therapy in ACS.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, the Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

    Faculty:
    Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
    Professor of Medicine
    Director, Cardiovascular Research
    Program Director, Interventional Cardiology Fellowship
    University of Florida College of Medicine -Jacksonville
    Jacksonville, FL 

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 

    Consulting Fees or Honoraria: Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company
    Payments for participation in review activities: CeloNova and St Jude Medical
    Institutional Research Grants: Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. 

    Reviewers/Content Planners/Authors:

    • The PIM planners and managers have nothing to disclose.
    • Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose. 
    • The Medtelligence planners and managers have nothing to disclose.
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Learning Objectives

    This case-based educational program is designed by distinguished experts in the field to provide the healthcare professional with information and guidance on the clinical issues and recent data regarding anticoagulation in patients with CAD and PAD. After participating in this educational activity, participants should be better able to:

    • Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
    • Relate the clinical implications of anticoagulation in patients with coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular diseases
    • Utilize non-VKA oral anticoagulants (NOACs) at the proper dose for patients with moderate or high risk of major polyvascular events, advising patients of the risks and benefits, and performing proper follow-up
    • Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, interventional cardiologists, internists, fellows, medical students, pharmacy professionals, and allied health professionals involved in the care of patients with CAD and PAD.

  • Accreditation and Credit Designation Statements

    Physician Continuing Education Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for
    Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and
    Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education
    for physicians.

    Credit Designation
    The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Evaluation by Course” and search by course ID 13277. Upon registering and successfully completing  the activity evaluation, your certificate will be made available immediately. 

  • Provider(s)/Educational Partner(s)

    Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in collaboration with Postgraduate Institute for Medicine (PIM).

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence in conjunction with PIM. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free